By PPN News Staff
The FDA approved a new lower cost HIV combination of efavirenz, lamivudine and tenofovir disoproxil fumarate (EFV-3TC-TDF, Symfi, Mylan) 600 mg/300 mg/300 mg tablets.
EFV-3TC-TDF will be a once-daily, single-tablet regimen, indicated as a complete regimen for the treatment of HIV infection in adult and pediatric patients weighing at least 40 kg.